PMID- 35082758
OWN - NLM
STAT- MEDLINE
DCOM- 20220331
LR  - 20220401
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 12
DP  - 2021
TI  - Trends in the Degree of Control and Treatment of Cardiovascular Risk Factors in 
      People With Type 2 Diabetes in a Primary Care Setting in Catalonia During 
      2007-2018.
PG  - 810757
LID - 10.3389/fendo.2021.810757 [doi]
LID - 810757
AB  - OBJECTIVE: To assess the trends in cardiovascular risk factor control and drug 
      therapy from 2007 to 2018 in subjects with type 2 diabetes mellitus (T2DM). 
      MATERIALS AND METHODS: Cross-sectional analysis using yearly clinical data and 
      treatment obtained from the SIDIAP database. Patients aged >/=18 years with a 
      diagnosis of T2DM seen in primary care in Catalonia, Spain. RESULTS: The number 
      of T2DM patients increased from 299,855 in 2007 to 394,266 in 2018. We also found 
      an increasing prevalence of cardiovascular disease, heart failure, and chronic 
      kidney disease (from 18.4 to 24.4%, from 4.5 to 7.3%, and from 20.2 to 31.3%, 
      respectively). The achievement of glycemic targets (HbA1c<7%) scarcely changed 
      (54.9% to 55.9%). Major improvements were seen in blood pressure (</=140/90 mmHg: 
      from 55% to 71.8%), and in lipid control (low-density lipoprotein cholesterol 
      <100 mg/dl: 33.4% to 48.4%), especially in people with established cardiovascular 
      disease (48.8 to 69.7%). Simultaneous achievement of all three targets improved 
      from 12.5% to 20.1% in the overall population and from 24.5% to 32.2% in those 
      with cardiovascular disease but plateaued after 2013. There was an increase in 
      the percentage of patients treated with any antidiabetic drug (70.1% to 81.0%), 
      especially metformin (47.7% to 67.7%), and DPP4i (0 to 22.6%). The use of SGLT-2 
      and GLP-1ra increased over the years, but remained very low in 2018 (5.5% and 
      2.1% of subjects, respectively). There were also relevant increases in the use of 
      statins (38.0% to 49.2%), renin-angiotensin system (RAS) drugs (52.5% to 57.2%), 
      and beta-blockers (14.3% to 22.7%). CONCLUSIONS: During the 2007-2018 period, 
      relevant improvements in blood pressure and lipid control occurred, especially in 
      people with cardiovascular disease. Despite the increase in the use of 
      antidiabetic and cardiovascular drugs, the proportion of patients in which the 
      three objectives were simultaneously achieved is still insufficient and plateaued 
      after 2013. The use of antidiabetic drugs with demonstrated cardio renal benefits 
      (SGLT-2 and GLP-1ra) increased over the years, but their use remained quite low.
CI  - Copyright (c) 2022 Mata-Cases, Vlacho, Real, Puig-Treserra, Bundo, Franch-Nadal and 
      Mauricio.
FAU - Mata-Cases, Manel
AU  - Mata-Cases M
AD  - Grup de Recerca Epidemiologica en Diabetis des de l'Atencio Primaria (DAP-CAT), 
      Unitat de Suport a la Recerca Barcelona, Fundacio Institut Universitari per a la 
      Recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, 
      Spain.
AD  - Centre d'Atencio Primaria La Mina, Gerencia d'Ambit d'Atencio Primaria de 
      Barcelona, Institut Catala de la Salut, Barcelona, Spain.
AD  - Centro de Investigacion Biomedica en Red de Diabetes y Enfermedades Metabolicas 
      Asociadas, (CIBERDEM), Barcelona, Spain.
FAU - Vlacho, Bogdan
AU  - Vlacho B
AD  - Grup de Recerca Epidemiologica en Diabetis des de l'Atencio Primaria (DAP-CAT), 
      Unitat de Suport a la Recerca Barcelona, Fundacio Institut Universitari per a la 
      Recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, 
      Spain.
FAU - Real, Jordi
AU  - Real J
AD  - Grup de Recerca Epidemiologica en Diabetis des de l'Atencio Primaria (DAP-CAT), 
      Unitat de Suport a la Recerca Barcelona, Fundacio Institut Universitari per a la 
      Recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, 
      Spain.
AD  - Centro de Investigacion Biomedica en Red de Diabetes y Enfermedades Metabolicas 
      Asociadas, (CIBERDEM), Barcelona, Spain.
FAU - Puig-Treserra, Ramon
AU  - Puig-Treserra R
AD  - Grup de Recerca Epidemiologica en Diabetis des de l'Atencio Primaria (DAP-CAT), 
      Unitat de Suport a la Recerca Barcelona, Fundacio Institut Universitari per a la 
      Recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, 
      Spain.
FAU - Bundo, Magdalena
AU  - Bundo M
AD  - Grup de Recerca Epidemiologica en Diabetis des de l'Atencio Primaria (DAP-CAT), 
      Unitat de Suport a la Recerca Barcelona, Fundacio Institut Universitari per a la 
      Recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, 
      Spain.
AD  - Centre d'Atencio Primaria Ronda Prim, Gerencia d'Ambit d'Atencio Primaria 
      Metropolitana Nord de Barcelona, Institut Catala de la Salut, Mataro, Spain.
FAU - Franch-Nadal, Josep
AU  - Franch-Nadal J
AD  - Grup de Recerca Epidemiologica en Diabetis des de l'Atencio Primaria (DAP-CAT), 
      Unitat de Suport a la Recerca Barcelona, Fundacio Institut Universitari per a la 
      Recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, 
      Spain.
AD  - Centro de Investigacion Biomedica en Red de Diabetes y Enfermedades Metabolicas 
      Asociadas, (CIBERDEM), Barcelona, Spain.
AD  - Primary Health Care Center Raval Sud, Gerencia d'Atencio Primaria, Institut 
      Catala de la Salut, Barcelona, Spain.
FAU - Mauricio, Didac
AU  - Mauricio D
AD  - Grup de Recerca Epidemiologica en Diabetis des de l'Atencio Primaria (DAP-CAT), 
      Unitat de Suport a la Recerca Barcelona, Fundacio Institut Universitari per a la 
      Recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, 
      Spain.
AD  - Centro de Investigacion Biomedica en Red de Diabetes y Enfermedades Metabolicas 
      Asociadas, (CIBERDEM), Barcelona, Spain.
AD  - Department of Endocrinology & Nutrition, Hospital de la Santa Creu i Sant Pau, 
      IIB Sant Pau, Spain.
AD  - Departament of Medicine, University of Vic, Central University of Catalonia, Vic, 
      Spain.
LA  - eng
PT  - Journal Article
DEP - 20220110
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - *Cardiovascular Diseases/epidemiology/etiology/prevention & control
MH  - Cross-Sectional Studies
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy/epidemiology
MH  - Heart Disease Risk Factors
MH  - Humans
MH  - Primary Health Care
MH  - Risk Factors
MH  - Spain/epidemiology
PMC - PMC8784522
OTO - NOTNLM
OT  - Type 2 dabetes
OT  - antidiabetic drugs
OT  - epidemiology
OT  - glycemic concrol
OT  - observational study
COIS- MM-C has received advisory honorarium from Astra-Zeneca, Bayer, Boehringer 
      Ingelheim, GSK, Lilly, MSD, Novartis, Novo Nordisk, and Sanofi; he has received 
      speaker honorarium from Astra-Zeneca, Bayer, Boehringer Ingelheim, GSK, Lilly, 
      Menarini, MSD, Novartis, Novo Nordisk, and Sanofi; he has received research 
      grants to the institution from Astra-Zeneca, GSK, Lilly, MSD, Novartis, Novo 
      Nordisk and Sanofi. JF-N has received advisory and or speaking fees from 
      Astra-Zeneca, Ascensia, Boehringer Ingelheim, GSK, Lilly, MSD, Novartis, Novo 
      Nordisk, and Sanofi; he has received research grants to the institution from 
      Astra-Zeneca. GSK, Lilly, MSD, Novartis, Novo Nordisk, Sanofi, and Boehringer. DM 
      has received advisory and/or speaking fees from Astra-Zeneca, Ascensia, 
      Boehringer Ingelheim, GSK, Lilly, MSD, Novartis, Novo Nordisk, and Sanofi; he has 
      received research grants to the institution from Astra-Zeneca, GSK, Lilly, MSD, 
      Novartis, Novo Nordisk, Sanofi, and Boehringer. MB has received advisory and 
      speaking fees from MSD. The remaining authors declare that the research was 
      conducted in the absence of any commercial or financial relationships that could 
      be construed as a potential conflict of interest.
EDAT- 2022/01/28 06:00
MHDA- 2022/04/01 06:00
PMCR- 2021/01/01
CRDT- 2022/01/27 05:48
PHST- 2021/11/07 00:00 [received]
PHST- 2021/12/16 00:00 [accepted]
PHST- 2022/01/27 05:48 [entrez]
PHST- 2022/01/28 06:00 [pubmed]
PHST- 2022/04/01 06:00 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2021.810757 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2022 Jan 10;12:810757. doi: 
      10.3389/fendo.2021.810757. eCollection 2021.